Description: Shanghai Medicilon Inc., a drug discovery contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. It offers chemistry services, including medicinal, synthesis, and analytical chemistry services, as well as process development services; and drug formulation services, such as pre-formulation and analytical development services, as well as research on quality control and clinical trial material services. The company also provides biology services comprising recombinant protein, crystallization and structural, discovery biology, computational biology and molecular modeling, and kinase services, as well as prepackaged M9 selenomethionine growth media kits and packages for growing cell culture in IPTG-inducible bacterial expression systems. In addition, it offers pharmacology services, including cancer xenograft, metabolic disease, inflammation and immunological, neurological disorders, and other disease models; services in the areas of in vitro ADME and in vivo pharmacokinetics; and bioanalytical services, such as large and small molecule services. Further, the company provides preclinical services comprising preclinical pharmacokinetic and safety evaluation. Shanghai Medicilon Inc. was founded in 2004 and is headquartered in Shanghai, China.
Home Page: www.medicilon.com.cn
585 Chuanda Road
Shanghai,
201299
China
Phone:
86 21 5859 1500
Officers
| Name | Title |
|---|---|
| Dr. Chunlin Chen Ph.D. | Co-Founder, CEO & Exec. Director |
| Ms. Binbin Liu | Chief Financial Officer |
| Mr. Shuangqing Peng Ph.D. | Head of Preclinical Research Department |
| Dr. Jinna Cai Ph.D. | Director & Deputy GM |
| Dr. Xuedong Dai Ph.D. | Exec. VP of International R&D Department |
| Mr. Xingquan Ma Ph.D. | Sr. VP of Chemistry |
| Mr. Xiaodong Zhang Ph.D. | VP & Head of Preclinical Research |
| Mr. Chao Xue | Board Sec. |
| Dr. Yongmei Xu Ph.D. | VP of R&D |
| Mr. Zhigang Li | VP of R&D |
Exchange: SHG
Country: CN : China
Currency: Renminbi (¥)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 49.7757 |
| Price-to-Book MRQ: | 11.4574 |
| Price-to-Sales TTM: | 10.6808 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 2440 |